Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of ASCT-83 in Healthy Adults
NCT07363395Phase 1Recruiting
- Sponsor
- Alcamena Stem Cell Therapeutics
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASCT-83 in neuropathic pain (11 arms), sponsored by Alcamena Stem Cell Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events, Changes in clinical safety parameters and 2 more. Started Jan 2026; status: recruiting.
02
Drugs
ASCT-83
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT07363395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363395.